China SXT Pharmaceuticals
SXTC
3 hedge funds and large institutions have $199K invested in China SXT Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
250% more capital invested
Capital invested by funds: $57K → $199K (+$142K)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
50% less funds holding
Funds holding: 6 → 3 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$94.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$6.15K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.57K |
| 4 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
-$5.26K |
| 5 |
HF
HRT Financial
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MG
1
Marex Group
London,
| $164K | +$94.6K | +34 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $25.4K | +$11.1K | +4 | +400% |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $10K | -$5.57K | -2 | -50% |
|
4
Qube Research & Technologies (QRT)
London,
United Kingdom
| $12 | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$23.5K | -6 | Closed |
|
|
HF
6
HRT Financial
New York
| – | -$5K | -2 | Closed |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$6.15K | -2 | Closed |
|
|
LFAS
8
Level Four Advisory Services
Dallas,
Texas
| – | -$5.26K | -1 | Closed |
|
|
BBA
9
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$1.42K | – | – |
|
SXTC Hedge Fund Activity: Q4 2023 in Review
3 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2023, worth a combined $199K — up 250% from $57K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SXTC and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Marex Group, opening a new position worth an estimated $94.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23.5K sold.
- 3 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q4 2023, down from 6 in Q3 2023.
- Funds reported $199K of China SXT Pharmaceuticals stock for Q4 2023, up 250% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q4 2023 and 4 closed out, a net change of -3 holders.
- The largest China SXT Pharmaceuticals buyer in Q4 2023 was Marex Group, an estimated $94.6K added.
- The largest China SXT Pharmaceuticals seller in Q4 2023 was Citadel Advisors, an estimated $23.5K sold.
Based on aggregated 13F filings for Q4 2023.